In researching current treatment plans for MS, I discovered an article from May 22, 2013 from the Multiple Sclerosis Association of America (MSAA) reviewing a new medication in trial called Plegridy. According to Biogen Idec this Phase III trial drug is “significantly reducing disease activity including relapses, disability progression and brain lesions, compared to placebo, and showed favorable safety and tolerability profiles at one year.” It could be 5-6 years before we see this drug if it gains FDA approval. With the longer half-life, it means one subcutaneous shot of interferon beta-1a every two or four weeks.